What is Corti?
Corti operates at the intersection of clinical medicine and applied artificial intelligence. The company has engineered a sophisticated software platform designed to augment healthcare personnel during patient consultations. By utilizing real-time audio processing, the system autonomously generates clinical notes, queries medical databases, and cross-references patient symptoms against millions of historical case files. This technological intervention ensures that practitioners can deliver optimal treatment protocols with increased accuracy and efficiency. As a leader in the health-tech sector, Corti is effectively reducing the administrative burden on medical staff while simultaneously improving diagnostic precision, positioning itself as an essential tool for digital health transformation.
How much funding has Corti raised?
Corti has raised a total of $92M across 3 funding rounds:
Angel/Seed
$5M
Series A
$27M
Series B
$60M
Angel/Seed (2019): $5M, investors not publicly disclosed
Series A (2021): $27M led by byFounders, Vaekstfonden, Hearcore, Id Invest, and Chr. Augustinus Fabrik
Series B (2023): $60M supported by EiFO, Atomico, and Eurazeo
Key Investors in Corti
Atomico
Atomico is a European Venture Capital firm headquartered in London, with offices in Paris, Berlin and Stockholm. Its founder and CEO is Niklas Zennström, a serial entrepreneur who co-founded Skype and Kazaa.
Eurazeo
Headquartered in Paris, Eurazeo is a leading global investment company with considerable private equity, venture capital, real estate, and private debt, supporting companies of all sizes in their development by offering deep sector expertise.
byFounders
byFounders VC is a community-powered early-stage venture fund that invests in globally ambitious teams connected to the Nordic and Baltic countries, providing operational expertise and a global network.
What's next for Corti?
With the successful closure of this major strategic investment, Corti is well-positioned to accelerate its international expansion and deepen its product capabilities. The company is expected to leverage this capital to enhance its AI models, ensuring broader compatibility with diverse healthcare systems and regulatory environments. As the firm transitions into a mature enterprise-level entity, the focus will likely shift toward scaling its operational footprint and forging deeper partnerships with global hospital networks. This infusion of resources provides the necessary runway to maintain its competitive edge in the rapidly evolving landscape of medical AI, ensuring that its diagnostic support tools remain at the forefront of clinical innovation.
See full Corti company page
